Concerning the investigated markers, to date, only CCRL1 was examined regarding its general gene expression in different molecular subtypes of GBM (isocitrate dehydrogenase mutant vs. wildtype, 1p19q codeletion vs. no codeletion). This evidence concerns the gene ACKR4 and glioblastoma.